These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
5. [Discovery of a New Siderophore Cephalosporin, Cefiderocol]. Yamano Y Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471 [TBL] [Abstract][Full Text] [Related]
6. Activity of Cefiderocol Against Iregui A; Khan Z; Landman D; Quale J Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915 [TBL] [Abstract][Full Text] [Related]
7. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections]. Kuai J; Wang X; Wang H Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469 [TBL] [Abstract][Full Text] [Related]
8. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence. Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312 [TBL] [Abstract][Full Text] [Related]
9. Compassionate use of cefiderocol for carbapenem-resistant Mabayoje DA; NicFhogartaigh C; Cherian BP; Tan MGM; Wareham DW JAC Antimicrob Resist; 2021 Jun; 3(Suppl 1):i21-i24. PubMed ID: 34223152 [TBL] [Abstract][Full Text] [Related]
11. Treatment of carbapenem-resistant Canton R; Doi Y; Simner PJ Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1077-1094. PubMed ID: 35502603 [TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria. Ong'uti S; Czech M; Robilotti E; Holubar M Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098 [TBL] [Abstract][Full Text] [Related]
13. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections. Drwiega EN; Griffith NC; Danziger LH Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628 [TBL] [Abstract][Full Text] [Related]
15. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint. Massol J; Dinh A; Jeannot K; Duran C; Bouchand F; Potron A; Dortet L; Jehl F J Glob Antimicrob Resist; 2024 Jun; 38():140-145. PubMed ID: 38844258 [TBL] [Abstract][Full Text] [Related]
18. Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Karruli A; Migliaccio A; Pournaras S; Durante-Mangoni E; Zarrilli R Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136764 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004 [TBL] [Abstract][Full Text] [Related]
20. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]